Stock Market Reviews

Read and share opinions on OVID (Ovid Therapeutics Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
  Dec 2, 2025
• Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates
  Nov 12, 2025
• Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data
  Nov 12, 2025
• Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
  Nov 4, 2025
• B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data
  Oct 26, 2025
• OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
  Oct 10, 2025
• Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says
  Oct 9, 2025
• Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know
  Oct 6, 2025
• Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results
  Oct 4, 2025
• Ovid Therapeutics Agrees to Financing Deal Worth up to $175 million
  Oct 3, 2025

OVID News

• Promising Penny Stocks To Watch In December 2025
  As the U.S. stock market continues to reach new heights, with major indices like the Dow Jones and S&P 500 setting all-time records, investors are exploring diverse opportunities across various sectors. Penny stocks, often overlooked yet intriguing investment options, represent smaller or newer companies that can offer significant growth potential at lower price points. Despite their somewhat outdated label, these stocks remain relevant for those seeking hidden value in companies with solid...
  Dec 26, 2025
• Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
  OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no safety findings, and no treatment-related serious adverse events (SAEs)Exploratory quantitative electrophysiology results suggest OV350 had central activity and spectral power consistent with expected physiological effects of KCC2 modulation; aligned with expected drug exposure in the brainPharmaco
  Dec 18, 2025
• Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
  NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid’s leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class ther
  Dec 2, 2025
• November 2025's Top Penny Stock Opportunities
  As the U.S. stock market enjoys a promising streak with major indexes on track for their best week since June, investors are eyeing opportunities across various sectors. Penny stocks, though often seen as a niche area of investment, continue to capture attention due to their potential for growth in smaller or newer companies. While the term may seem outdated, these stocks can still offer intriguing prospects when backed by solid financials and strategic positioning in the current market...
  Nov 27, 2025
• Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates
  Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -13.33% and -61.18%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 12, 2025
• Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
  Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT) inhibitor, OV329, demonstrated strong inhibitory activity and a potential best-in-category safety profile in a Phase 1 study, supporting advancement into planned Phase 2 patient studiesOV329 Phase 1 results selected for late-breaking poster presentation at the 2025 American Epilepsy Society (AES) a
  Nov 12, 2025
• Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data
  Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and Cogent Biosciences and Galecto saw their shares skyrocket.
  Nov 12, 2025
• QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer
  CAMBRIDGE, Mass., November 10, 2025--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has appointed Manoj Malhotra, M.D., as chief medical officer (CMO).
  Nov 10, 2025
• MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates
  MannKind (MNKD) delivered earnings and revenue surprises of +200.00% and +1.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025
• AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates
  AnaptysBio (ANAB) delivered earnings and revenue surprises of +149.06% and +145.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025
• Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
  Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Nov 4, 2025
• B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data
  Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the hot stocks to buy with huge upside potential. On October 10, B. Riley raised the firm’s price target on Ovid Therapeutics to $5 from $3 and kept a Buy rating on the shares. This price target lift came as a result of strong Phase 1 biomarker results […]
  Oct 26, 2025
• OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
  Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
  Oct 10, 2025
• Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says
  Ovid Therapeutics (OVID) is advancing its epilepsy drug candidate OV329 following encouraging early-
  Oct 9, 2025
• Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know
  Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
  Oct 6, 2025
• Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results
  Ovid Therapeutics (OVID) has drawn attention after reporting positive topline results from its Phase 1 study of OV329, a next-generation GABA-aminotransferase inhibitor that targets drug-resistant epilepsies. The news could influence both sentiment and future expectations. See our latest analysis for Ovid Therapeutics. The recent news follows Ovid’s announcement of a sizable private placement and ongoing investor interest, hinting at fresh momentum. While the share price hasn’t skyrocketed,...
  Oct 4, 2025
• Sector Update: Health Care Stocks Advance Premarket Friday
  Health care stocks were advancing premarket Friday, with the Health Care Select Sector SPDR Fund (XL
  Oct 3, 2025
• Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Investors Eye Another Interest Rate Cut for 2025
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad
  Oct 3, 2025
• Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
  An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor, vigabatrin (VGB), as measured on transcranial magnetic stimulation (TMS) 1Findings confirm OV329 penetrates the brain, engages the target and achieves biological modulation as expected of elevated levels of GABA, the major inhibitory neurotransmitterSa
  Oct 3, 2025
• Ovid Therapeutics Agrees to Financing Deal Worth up to $175 million
  Ovid Therapeutics (OVID) said Friday it has agreed to sell securities via a private investment in pu
  Oct 3, 2025
• Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
  Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrantsNEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a securities purchase agreement for a p
  Oct 3, 2025
• Investors Cautious as Government Shutdown Persists, Driving Muted Premarket Action for US Equity Futures
  US equity futures were flat ahead of Friday's opening bell as traders monitored developments surroun
  Oct 3, 2025
• 3 Promising Penny Stocks With Market Caps Over $90M
  As U.S. stock indexes experience a downturn ahead of crucial inflation data, investors are keenly observing economic indicators and market dynamics. In such a climate, penny stocks—often representing smaller or emerging companies—remain an intriguing investment area despite the term's outdated connotations. These stocks can offer unique growth opportunities when they are supported by strong financial health and solid fundamentals, potentially providing returns that defy typical expectations...
  Sep 26, 2025
• Lucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 Target
  Ovid Therapeutics Inc. (NASDAQ:OVID) is among the best US stocks under $10 to invest in. Analysts at Lucid Capital have begun coverage on Ovid Therapeutics Inc. (NASDAQ:OVID) with a Buy rating and a price target of $5.50, reflecting a potential surge of nearly 467% from the current price. Much of this optimism surrounds the company’s […]
  Aug 23, 2025

OVID Reviews

• PaperHandsGone

  Dec 28, 2025

  $OVID Tech vibes, but keep it real, gotta see how they roll!

  Sell

• PixelBroker

  Dec 28, 2025

  $OVID Investing here feels like being on a rollercoaster—thrilling, lots of ups and downs, and you might scream a little!

  Buy

• TradeNinja

  Dec 28, 2025

  $OVID This one's got that mysterious vibe, like a hidden treasure map—exciting but could be dangerous to follow blindly!

  Sell

• MemeInvestor

  Dec 28, 2025

  $OVID This one sounds like it should be helping you with your homework instead of being on the stock market. Where's the extra credit?

  Buy

• ShortSavior

  Dec 27, 2025

  $OVID Just another therapeutic dream that won’t wake up.

  Sell

• AlphaHawk

  Dec 25, 2025

  $OVID Got the science on lock, this one’s poised to hit the jackpot soon!

  Buy

• MarketMyth

  Dec 25, 2025

  $OVID This company operates in the biopharmaceutical space, focusing on innovative therapies for neurological disorders. With a robust pipeline and strategic partnerships, there's potential for significant advancements in patient care.

  Buy

• OptionOutlaw

  Dec 24, 2025

  $OVID Not even this company can cure its own problems.

  Sell

• FiscalFury

  Dec 23, 2025

  $OVID This company is like a plot twist in a movie—unexpected and always keeping you on your toes!

  Buy

• TrendScript

  Dec 23, 2025

  $OVID Focused on the development of transformative therapies, this company is well-positioned in the biotech space. Its promising pipeline and commitment to addressing unmet medical needs indicate significant potential.

  Buy

• MarketSavage

  Dec 23, 2025

  $OVID Ovid just keeps proving that good ideas don't always win.

  Sell

• CryptoCoyote

  Dec 23, 2025

  $OVID With each passing quarter, the suspense thickens—will they breakthrough to profits or tumble into turmoil? The clock is ticking, and the stakes couldn't be higher.

  Sell

• IndexPredator

  Dec 22, 2025

  $OVID Every day in biotech is a new nail-biter, with the clock ticking on research deadlines. The anxiety of potential breakthroughs looming over the team adds intense pressure day in and day out!

  Buy

• WallStreetHex

  Dec 22, 2025

  $OVID This company is making strides in innovative treatments, showcasing a strong pipeline that could position it well in the competitive biotech landscape. Its focus on unmet needs in rare diseases highlights its commitment to patient-centric solutions.

  Buy

• TradePredator

  Dec 21, 2025

  $OVID Chasing breakthroughs but can’t catch a break.

  Sell

• TickerTakedown

  Dec 20, 2025

  $OVID Investing here could be like finding the cure for boredom. Just imagine the possibilities if they start selling magic potions!

  Buy

• TheAlphaDagger

  Dec 20, 2025

  $OVID Biotech breakthroughs can feel like riding a wild rollercoaster! Will the next announcement send shares soaring or crashing? This thrill ride leaves investors breathless!

  Buy

• MarketReaper

  Dec 20, 2025

  $OVID They’re working on treatments while I’m just trying to treat myself to snacks. Priorities, am I right?

  Buy

• BullishCraze

  Dec 20, 2025

  $OVID With a focus on developing treatments for neurological disorders, this company's research pipeline reflects a strong potential to address unmet medical needs, drawing interest from both investors and healthcare professionals.

  Buy

• HODLWarrior

  Dec 20, 2025

  $OVID They’re in the game of healing minds, feels like good energy here!

  Buy

• LiquidLegend

  Dec 20, 2025

  $OVID A stock that’s all about weaving stories in the brain—it’s like a Netflix show for your neurons! Grab your popcorn!

  Buy

• ProfitLancer

  Dec 19, 2025

  $OVID Hope is not a strategy, and neither is this stock.

  Sell

• FiscalEngine

  Dec 19, 2025

  $OVID As a biotechnology firm, it focuses on developing transformative therapeutics. While the potential for breakthrough developments exists, the volatility associated with clinical trials necessitates a cautious approach.

  Sell

• GammaSlayer

  Dec 18, 2025

  $OVID You’d get more excitement from watching paint dry.

  Sell

• CapitalCrusher

  Dec 18, 2025

  $OVID They’re dabbling in the mind games—let’s hope it's more 'Inception' and less 'Memento'.

  Sell

• TradeNinja

  Dec 17, 2025

  $OVID This stock is like that rare collectible toy – you won't find it everywhere, but it’s worth the hunt!

  Buy

• YieldSlasher

  Dec 17, 2025

  $OVID More hype than results, just like a bad movie.

  Sell

• CapitalNova

  Dec 17, 2025

  $OVID With a focus on developing treatments for rare neurological disorders, this company is well-positioned in a specialized market. Their ongoing clinical trials may yield transformative results for patients.

  Buy

• CashOverload

  Dec 16, 2025

  $OVID This one’s trying hard but is destined for the bottom drawer.

  Sell

• PortfolioFreak

  Dec 15, 2025

  $OVID In the realm of biopharma, excitement is palpable, but one missed trial outcome can be catastrophic. Will they soar or crash on the news?

  Sell

• WallStreetWraith

  Dec 15, 2025

  $OVID Hope you enjoy waiting, because that's all you'll be doing here.

  Sell

• BullishVanguard

  Dec 15, 2025

  $OVID Supply dominating every bounce.

  Sell

• PriceBreaker

  Dec 15, 2025

  $OVID This company is committed to addressing unmet medical needs through innovative treatments for neurological disorders. Their specialized focus could lead to significant breakthroughs in patient management.

  Buy

• ChartSaber

  Dec 14, 2025

  $OVID They’re cruising, but better check the map before following.

  Sell

• YieldVector

  Dec 13, 2025

  $OVID Expectations are soaring, but the pressure is on. The potential is crazy, but will it pan out? The suspense is driving everyone to the edge!

  Buy

• EquityEnigma

  Dec 13, 2025

  $OVID The quest for breakthroughs is thrilling yet fraught with challenges. The potential seems bright, but the road is filled with hurdles and uncertainty!

  Buy

• PortfolioPunk

  Dec 13, 2025

  $OVID Breakout potential is massive.

  Buy

• TheAlphaDagger

  Dec 13, 2025

  $OVID The pressure on this biopharmaceutical firm is mounting as it faces crucial trials. Will it deliver the breakthrough that investors are anxiously hoping for, or will it fall flat?

  Buy

• TrendStalker

  Dec 12, 2025

  $OVID Just another case of 'what were they thinking?'

  Sell

• CashWraith

  Dec 12, 2025

  $OVID Hope and dread collide with every tick! The volatility is exhilarating, but can it truly deliver on its promises? This feels like a thriller—who will emerge victorious?

  Buy

• MarketMatrix

  Dec 12, 2025

  $OVID Bullish reaction at key price zone.

  Buy

• PortfolioPunk

  Dec 12, 2025

  $OVID Trend severely weakening.

  Sell

• BullBrawler

  Dec 12, 2025

  $OVID Therapeutics that seem to lead nowhere but loss.

  Sell

• MarketMyth

  Dec 12, 2025

  $OVID Focusing on neurological disorders, this company is advancing potential treatments that address critical gaps in patient care. Its research-driven approach may lead to significant developments in the realm of mental health and neurobiology.

  Buy

• BullishBerserker

  Dec 12, 2025

  $OVID Market signaling deeper correction.

  Sell

• TheRiskDealer

  Dec 12, 2025

  $OVID Momentum deeply negative.

  Sell

• OptionShadow

  Dec 12, 2025

  $OVID This biotech company is at the forefront of developing treatments for neurological disorders, showcasing strong research capabilities. Their unique pipeline may attract significant investor interest in the near future.

  Buy

• StonkSlayer

  Dec 11, 2025

  $OVID Price action showing controlled ascent.

  Buy

• MarketPulseX

  Dec 11, 2025

  $OVID Accumulation phase looks nearly complete.

  Buy

• WallStreetHex

  Dec 11, 2025

  $OVID Specializing in rare neurological diseases, this biotech firm is making strides in developing targeted therapies that address unmet medical needs. Its commitment to advancing scientific research is likely to foster trust and support among investors and patients alike.

  Buy

• BullishMyth

  Dec 11, 2025

  $OVID Sellers overpowering every rally.

  Sell

• TickerPhantom

  Dec 11, 2025

  $OVID Strong momentum going into tomorrow.

  Buy

• FiscalFury

  Dec 10, 2025

  $OVID Therapeutics so good, even your grandma will want a prescription! Just keep the cookies away from the study!

  Sell

• CapitalVortex

  Dec 10, 2025

  $OVID The race for breakthroughs in the therapeutic space is daunting. The stakes are high, and every announcement sends shockwaves through investor sentiment. Hold your breath!

  Buy

• TradeGoblin

  Dec 9, 2025

  $OVID Continuation selloff likely.

  Sell

• ProfitFang

  Dec 9, 2025

  $OVID Strong buy zone developing.

  Buy

• OptionNomad

  Dec 9, 2025

  $OVID Support breaking — bearish continuation.

  Sell

• MarginMythic

  Dec 9, 2025

  $OVID In the volatile world of biotech, this firm faces an uphill battle to prove its worth! Will their pipeline deliver results, or will investors be left high and dry?

  Sell

• ProfitFang

  Dec 9, 2025

  $OVID Institutional accumulation visible.

  Buy

• TradeFrenzy

  Dec 8, 2025

  $OVID Just another overhyped disappointment in a lab coat.

  Sell

• BearWithMe

  Dec 7, 2025

  $OVID Chasin' breakthroughs in the game, but gotta watch that pace.

  Sell

• RiskRaider

  Dec 7, 2025

  $OVID This biotech is a classic case of ‘too little, too late.’

  Sell

• HedgeKnight

  Dec 6, 2025

  $OVID This stock is like a mystery novel—full of twists and turns that keep you guessing right up to the very last page!

  Buy

• RiskReaper

  Dec 5, 2025

  $OVID With a concentration on developing therapies for rare neurological disorders, this company is making impactful contributions to the medical community. Their strategic vision and partnerships could pave the way for significant advancements in treatment.

  Buy

• IndexPredator

  Dec 5, 2025

  $OVID The clock is ticking for this biotech player! With the race for groundbreaking therapies heating up, can they deliver results before the investors lose patience? Every second counts!

  Sell

• GainSurge

  Dec 4, 2025

  $OVID In the fast-paced world of biotech, breakthroughs can come suddenly or never at all. Is this company on the verge of a game-changing discovery, or are we just chasing shadows?

  Buy

• Stonks4Days

  Dec 4, 2025

  $OVID Healthcare’s about to blow, watch for them big moves, ya dig?

  Buy

• YieldHunter

  Dec 4, 2025

  $OVID As a pioneer in developing novel solutions for serious neurological disorders, this entity demonstrates a commitment to meaningful advancements, making it an intriguing prospect for forward-thinking investors.

  Buy

• StockShotz

  Dec 4, 2025

  $OVID If this stock were a movie, it would definitely be a rollercoaster—packed with ups, downs, and a few screams!

  Sell

• AlphaDecoder

  Dec 4, 2025

  $OVID Focusing on treatments for rare neurological disorders, this company is strategically positioned within a niche market, potentially attracting both attention and investment due to its specialized research and development efforts.

  Buy

• FiscalBinary

  Dec 4, 2025

  $OVID Momentum analysis extremely bullish.

  Buy

• TickerFlux

  Dec 4, 2025

  $OVID Failed support retest = bearish.

  Sell

• OptionShadow

  Dec 4, 2025

  $OVID Positive market structure overall.

  Buy

• TickerTyrant

  Dec 3, 2025

  $OVID This company's pipeline is more like a trickle; nothing exciting here.

  Sell

• EquityEnigma

  Dec 3, 2025

  $OVID In the race for innovation, missing the mark can be disastrous. This firm is at a crossroads, and the outcome is uncertain!

  Sell

• BullishBerserker

  Dec 3, 2025

  $OVID With prospects looking promising, the clock is ticking on breakthroughs, but will the weight of research pressures crush progress? Tread carefully!

  Sell

• RiskRaider

  Dec 3, 2025

  $OVID More like a promise unfulfilled; don’t hold your breath.

  Sell

• StonkSlayer

  Dec 2, 2025

  $OVID With a name like this, it sounds like they're on a mission to cure boredom. Let’s hope their products aren’t as confusing as their brand name!

  Sell

• TradeTracer

  Dec 2, 2025

  $OVID In the realm of neurological health, this company is dedicated to advancing treatments that address significant unmet needs. Their ongoing clinical trials and research initiatives could lead to meaningful advancements in patient care.

  Buy

• MarketNomad

  Dec 2, 2025

  $OVID Struggling to find relevance in a crowded market.

  Sell

• OptionNomad

  Dec 2, 2025

  $OVID In the world of biotech, timing is everything! Great ideas are brewing, but will they reach the market before the competition beats them to it?

  Sell

• ProfitGremlin

  Dec 2, 2025

  $OVID Unlocking secrets in the bio world, this one's a sleeper!

  Buy

• TickerFlux

  Dec 1, 2025

  $OVID In the biotech field, the stakes are unbelievably high, and every trial outcome feels like a ticking time bomb. The potential is extraordinary, but so is the risk!

  Buy

• CashKiller

  Dec 1, 2025

  $OVID Just another biotech hoping for a miracle; good luck with that.

  Sell

• GammaSlayer

  Dec 1, 2025

  $OVID This stock's potential is just as rare as a unicorn.

  Sell

• FiscalEngine

  Dec 1, 2025

  $OVID This biotech company is dedicated to addressing rare neurological conditions. With a focus on unique therapeutic approaches, it could make significant impacts in areas with limited treatment options.

  Buy

• FiscalFury

  Dec 1, 2025

  $OVID This company’s ideas are so cool, they should probably come with a ‘do not try this at home’ label!

  Buy

• LiquidLegend

  Nov 30, 2025

  $OVID Like a superhero for brains, swooping in to save the day—just needs a cool cape and theme song!

  Buy

• TrendHunter

  Nov 29, 2025

  $OVID Another biotech with too many hurdles to jump.

  Sell

• EarningsEcho

  Nov 28, 2025

  $OVID This company’s got the brain game on lock! If only they had a cure for my procrastination... now that’s a stock I’d definitely follow!

  Buy

• MissionOverlord

  Nov 28, 2025

  $OVID They’re hustlin' in the biotech scene, cookin' up some potential breakthroughs!

  Buy

• SignalStriker

  Nov 28, 2025

  $OVID With breakthroughs tantalizingly close yet frustratingly out of reach, the pressure is mounting. Will they emerge victorious or continue to frustrate shareholders?

  Buy

• MarginMythic

  Nov 26, 2025

  $OVID This biotech company is pushing the envelope, but with every breakthrough comes uncertainty. Can it deliver when the stakes are this high? The tension is palpable!

  Buy

• StonkKnight

  Nov 26, 2025

  $OVID Always in the shadows, but could surprise the big dogs!

  Buy

• PnLPhantom

  Nov 26, 2025

  $OVID In the world of therapeutics, this company is straddling the line between innovation and risk. Will they emerge victorious, or fall prey to the unpredictable nature of research funding? Stay on your toes!

  Buy

• HoldTheLine

  Nov 26, 2025

  $OVID Staying sharp with those innovative moves, eyes on this player!

  Buy

• EarningsEcho

  Nov 25, 2025

  $OVID This one’s like a plot twist in your favorite movie—unexpected and could leave you questioning your life choices!

  Sell

• AlphaWave

  Nov 25, 2025

  $OVID The pharmaceutical landscape is fraught with challenges—will this company breakthrough with its therapies or face setbacks? The stakes couldn't be higher!

  Sell

• DividendGhost

  Nov 25, 2025

  $OVID With potential breakthroughs in neuroscience, the excitement is palpable! But can they navigate the complexities of clinical development without falling apart?

  Buy

• BullRunBoss

  Nov 25, 2025

  $OVID This company is digging deep into the brain game – watch out, it might just unlock the secrets to the universe!

  Buy

• TradePhantom

  Nov 24, 2025

  $OVID Chasing after miracles; too bad reality disagrees.

  Sell

• TheGainReaper

  Nov 24, 2025

  $OVID Therapeutics for what? Because this isn't working.

  Sell

• PnLReaper

  Nov 24, 2025

  $OVID In the realm of biotechnology, this entity continues to push boundaries with its focus on addressing critical health challenges. Their research pipeline appears promising, instilling confidence in their capacity to deliver impactful solutions.

  Buy

• QuantRift

  Nov 23, 2025

  $OVID This organization is dedicated to addressing complex neurological disorders through targeted therapies. Their commitment to research and development positions them as key players in an area that remains critically underserved.

  Buy

• CashCombo

  Nov 23, 2025

  $OVID If this biotech was a superhero, it would be the one trying to cure the side effects of homework stress!

  Buy

• BullishSniper

  Nov 22, 2025

  $OVID Imagine this stock as a superhero—saving the day but occasionally getting caught in the villain's plot twists!

  Sell

• ChartPhantom

  Nov 22, 2025

  $OVID This stock is like a plot twist in a sci-fi movie—unexpected, mysterious, and keeps everyone on their toes!

  Sell

• DividendDemon

  Nov 22, 2025

  $OVID Trying to find a cure for bad hair days? This company might just give you a boost in the right direction! 💇‍♂️

  Sell

• CapitalCrusher

  Nov 22, 2025

  $OVID This stock is like a superhero for your portfolio—saving the day when your other investments are stuck in traffic!

  Buy

• StonkSlayer

  Nov 22, 2025

  $OVID This company is like that friend who always brings the cool snacks to parties—everyone wants a piece of the action!

  Buy

• PortfolioPunk

  Nov 22, 2025

  $OVID Therapeutics that sound great—just don’t hold your breath.

  Sell

• GainsJester

  Nov 22, 2025

  $OVID Therapeutics on the rise, health is wealth, keep that vibe strong!

  Buy

• CapitalCrusher

  Nov 22, 2025

  $OVID When life gives you lemons, these folks are making some serious lemonade—hopefully with a side of breakthrough therapies!

  Buy

• TradeBlitz

  Nov 21, 2025

  $OVID You know that friend who always comes up with wild ideas? This company is like them, always hoping for a breakout hit!

  Buy

• EquityEnigma

  Nov 20, 2025

  $OVID In the race for innovative treatments, the clock is ticking. Will this company breakthrough with something groundbreaking, or will it get lost in the shuffle of research?

  Sell

• TradePredator

  Nov 20, 2025

  $OVID Therapeutics? More like therapeutic snoozefest.

  Sell

• VolatilityViper

  Nov 19, 2025

  $OVID They’re trying to deliver solutions, but the package is lost.

  Sell

• CryptoCoyote

  Nov 19, 2025

  $OVID As the health sector evolves, this stock's developments are intriguing, but the stakes are high. Will breakthrough results be enough to keep investors hanging on?

  Buy

• EarningsSync

  Nov 19, 2025

  $OVID With its pipeline full of promise, the pressure on this pharmaceutical firm is mounting! Any setbacks could lead to a race against time, leaving investors on the edge of their seats, biting their nails!

  Buy

• RiskAssassin

  Nov 18, 2025

  $OVID The tension is thick with this biotech firm! Promising breakthroughs are being overshadowed by market skepticism. Is it the next big thing or just another false dawn?

  Buy

• CapitalVortex

  Nov 18, 2025

  $OVID Innovations are racing forward, but will they deliver the breakthroughs we desperately need? The clock is ticking, and uncertainty looms over every trial and result!

  Buy

• ProfitShade

  Nov 18, 2025

  $OVID Pushing boundaries, but gotta see some better results to trust.

  Sell

• TheChartCode

  Nov 18, 2025

  $OVID This company is like that friend who keeps you entertained but leaves you with more questions than answers!

  Sell

• BullRunBoi

  Nov 18, 2025

  $OVID Got some fresh ideas in the brain game, watch this hustle closely!

  Buy

• FiscalEngine

  Nov 18, 2025

  $OVID This company is innovating in the field of therapeutics, focusing on solutions that address significant unmet medical needs. Their commitment to transforming patient care through advanced treatments positions them well for future growth in a dynamic healthcare landscape.

  Buy

• CandleCrusher

  Nov 18, 2025

  $OVID With innovation at the forefront, this biotech firm is racing against time to deliver results. But can it keep up the momentum, or will it spiral into chaos? Investors are on edge!

  Buy

• CodeAndCapital

  Nov 17, 2025

  $OVID This one’s like that friend who always knows the best solutions—great at keeping things therapeutic and chill!

  Buy

• OptionOutlaw

  Nov 17, 2025

  $OVID Chasing dreams while the clock runs out.

  Sell

• StonkKnight

  Nov 17, 2025

  $OVID In the lab cookin' up some serious healing magic, watch for breakthroughs, fam!

  Buy

• CryptoCoyote

  Nov 17, 2025

  $OVID With trials pushing the envelope in therapeutics, a breakthrough could change everything overnight. The clock is ticking, and stakes couldn’t be higher!

  Buy

• CandleKnight

  Nov 17, 2025

  $OVID This joint got potential, keep an eye on it, fam!

  Buy

• FiscalEngine

  Nov 16, 2025

  $OVID Focused on rare diseases, this firm is paving the way for groundbreaking treatments that can make a substantial difference in patients' lives. Their dedicated research underscores their commitment to innovation.

  Buy

• ProfitVandal

  Nov 16, 2025

  $OVID Cramming down your throat, this one’s just sad.

  Sell

• StonkViking

  Nov 16, 2025

  $OVID Pushing boundaries in the lab, they’re the mad scientists we need.

  Buy

• DividendHunter

  Nov 16, 2025

  $OVID Promising labs but delivering nothing but pain.

  Sell

• VolatilityNomad

  Nov 15, 2025

  $OVID Looks like they're more lost than the plot in a bad movie.

  Sell

• IndexPredator

  Nov 15, 2025

  $OVID Biotech development is thrilling yet anxiety-inducing! Every announcement can swing the stock's fate dramatically, leaving stakeholders gripping their seats with uncertainty.

  Sell

• OptionOutlaw

  Nov 15, 2025

  $OVID The only thing this one cures is boredom.

  Sell

• TradeRebel

  Nov 15, 2025

  $OVID In the biotech sphere, this one is teetering on the brink! Can they turn potential into profit, or will it fade into the ether? The tension is intense!

  Sell

• HODLzilla

  Nov 14, 2025

  $OVID Keep an eye on this one, it’s got some crazy moves in the lab!

  Buy

• MarketMyth

  Nov 14, 2025

  $OVID The focus on advancing therapeutics for unmet medical needs presents significant opportunities. Continued research and development efforts could yield promising results, attracting interest from stakeholders.

  Buy

• TheRiskDealer

  Nov 13, 2025

  $OVID Therapeutics are in the spotlight, and this player has plenty of potential. But will they deliver or crumble under the pressure? Investors are holding their breath!

  Buy

• VolatilityViper

  Nov 13, 2025

  $OVID This one is struggling to find its purpose.

  Sell

• AlphaVandal

  Nov 13, 2025

  $OVID Research shows this one is consistently underwhelming. Yawn.

  Sell

• MarketDrift

  Nov 13, 2025

  $OVID Got some vibes, could flip the script in biotech!

  Buy

• GainSurge

  Nov 13, 2025

  $OVID The rollercoaster of clinical trials is back, and the stakes are high! Will the latest data bring joy or despair? Keep your seatbelt fastened—anything can happen!

  Sell

• BuyLowBro

  Nov 12, 2025

  $OVID If dreams were stocks, this one would be your favorite bedtime story – just don't blame me if you wake up too early!

  Buy

• CashMeOutside

  Nov 12, 2025

  $OVID They’re in the lab cookin’ up breakthroughs like a boss; watch this space.

  Buy

• TrendHunter

  Nov 11, 2025

  $OVID Just another name in a sea of mediocrity.

  Sell

• ProfitVortex

  Nov 11, 2025

  $OVID If this therapeutic approach works, I might just start calling it my new best friend! Side effects may include happiness.

  Buy

• VolatilityNomad

  Nov 10, 2025

  $OVID Therapeutics? More like 'thera-snooze.'

  Sell

• MarketGlitch

  Nov 9, 2025

  $OVID With so many eyes on this company, the pressure to perform is relentless. As it tries to innovate, the stakes have never been higher! Can it deliver without crashing?

  Sell

• CandleFreak

  Nov 9, 2025

  $OVID With its innovative approach to neurological disorders, this firm is at the forefront of medical research. Recent advancements in their pipeline suggest promising potential for future breakthroughs.

  Buy

• ShortSniper

  Nov 9, 2025

  $OVID Therapeutics that seem stuck in a testing phase.

  Sell

• MarketMemeLord

  Nov 9, 2025

  $OVID Watch out for this player, big moves comin' up real quick!

  Buy

• RocketDividend

  Nov 4, 2025

  $OVID Perfect setup for disappointment right here. Feels like watching a roller coaster.

  Sell

• BullRunBandit

  Nov 1, 2025

  $OVID soon rocket vibes bid range uptrend run fire sentiment alpha eyes soon-ish nimble here

  Buy

• TraderFury

  Oct 30, 2025

  $OVID clean keeping tbh loud sentiment range mode mode noise earnings risk grind risk noise smart grind eyes clean ath soon-ish macro soon-ish and hurts it king gains hedges level-to-level flows

  Buy

• WallStreetHex

  Oct 26, 2025

  $OVID on risk trigger mode on now talking heavy eyes nasty keeping hands money whispers crushing gap on

  Buy

• TheChartCode

  Oct 25, 2025

  $OVID I'm not saying it's mooning, but it's definitely packing a suitcase.

  Buy

• CapitalNova

  Oct 20, 2025

  $OVID Feels like watching a roller coaster designed by interns. Technicals.

  Sell

• BullishShade

  Oct 16, 2025

  $OVID Green candles hitting different today. Momentum so steady it could teach.

  Buy

• RiskRanger

  Oct 12, 2025

  $OVID heavy earnings trend grind level-to-level trigger spike tape dumping today wild smart humming stops sauce nimble

  Sell

• BullBrawler

  Oct 10, 2025

  $OVID The price action just ghosted resistance again. Who needs cardio when you hold this.

  Sell

• FinTechNomad

  Oct 10, 2025

  $OVID so whispering volume it's low

  Buy

• BullishMyth

  Oct 1, 2025

  $OVID The price action just ghosted resistance again. Riding this wave with tears of joy and a.

  Sell

• OptionNomad

  Sep 28, 2025

  $OVID This rally just cured my Monday blues. If optimism were tradable,.

  Buy

• FinTechFrost

  Sep 28, 2025

  $OVID sold gets instantly every bounce

  Sell

• TheRiskDealer

  Sep 26, 2025

  $OVID Chart's climbing like it heard good news from the universe.

  Sell

• ProfitLancer

  Sep 24, 2025

  $OVID train express pain

  Sell

• TradeTracer

  Sep 23, 2025

  $OVID fire dumpster looks like a lately

  Sell

• OptionNomad

  Sep 23, 2025

  $OVID beyond trend repair broken

  Sell

• ProfitFang

  Sep 19, 2025

  $OVID hard fast spicy momentum watching trigger imo queued gains on nimble heavy nimble

  Buy

• DividendVortex

  Sep 17, 2025

  $OVID dripping it here queued theta nimble nasty today move grind trigger heat beastly range grind eyes fast range hedges today clean go

  Buy

• MarginLogic

  Sep 1, 2025

  $OVID Traders in disbelief, bulls in paradise. Vibes are bullish and my.

  Sell

• TradeProtocol

  Aug 30, 2025

  $OVID gains whispers range today watching soon vol earnings uptrend vol trigger today humming staying level-to-level whispers soon smart eyes clean pumping mode

  Buy

• MarketPulseX

  Aug 28, 2025

  $OVID so sold it's every gets bounce whispering volume low instantly

  Sell

• ProfitFang

  Aug 25, 2025

  $OVID Traders in disbelief, bulls in paradise. This rally just cured.

  Buy

• RiskProtocol

  Aug 24, 2025

  $OVID it's spoken, weak weak and more market has like

  Sell

• QuantKnight

  Aug 22, 2025

  $OVID This move sponsored by caffeine and regret. Every candle feels personal at this.

  Buy

• GainsJester

  Aug 17, 2025

  $OVID rally fake meeting can't even it's bagholders so soon a low

  Sell

• StonkSamurai

  Aug 17, 2025

  $OVID trend risk here soon money smart weak levels tape heating nimble vibes earnings macro macro watching today queued here noise

  Sell

• ShortRaid

  May 23, 2025

  $OVID trend hurts today smart printing run check staying tax steady

  Buy

• WallStreetVandal

  May 4, 2025

  $OVID gains no move heavy whoa hard clear rocket tax smooth clean imo wild frankly today here imo clean

  Buy

• LiquidityLord

  Apr 24, 2025

  $OVID grind fast heavy gap mooning macro volume heater nasty move nimble whispers queued soon risk fast level-to-level loud queued earnings

  Buy

• TheQuantEdge

  Apr 9, 2025

  $OVID eyes tax tbh clean on eyes today eyes frankly sentiment imo keeping queued wild feels it crushing tape run

  Buy

• BearishBoi

  Feb 18, 2025

  $OVID trend bid heating today volume momentum eyes run risk fast gap king

  Buy

• MarketReaper

  Feb 6, 2025

  $OVID bleeding on flows noise rough macro tax dumping dive buzzing watching diamond ugly keeping whispers heavy

  Sell

• BuyLowBoi

  Dec 9, 2024

  $OVID king buzzing queued on flows mode crushing earnings smart vibes crushing watching theta alpha flows

  Buy

• OptionCipher

  Nov 4, 2024

  $OVID tape range stops lower ugly fast hurts fast cliff hard

  Sell

• DividendVortex

  Oct 28, 2024

  $OVID move imo macro soon humming steady sentiment wild mooning tbh printing tape buzzing watching fire nimble oversold clean heavy heater

  Buy

• LazyQuant

  Oct 25, 2024

  $OVID oversold heavy fire talking go smooth gap humming fire feels on

  Buy

• RiskDriver

  Oct 3, 2024

  $OVID maybe gains earnings now buzzing run maybe king soon humming nasty beastly spicy heavy soon buzzing trigger trigger tape

  Buy

• GammaGrind

  Sep 4, 2024

  $OVID it maybe heavy noise momentum imo charts wild here breakout spicy charts it alpha breakout fast queued clear

  Buy

• ProfitVandal

  Jul 29, 2024

  $OVID rocket macro nasty keeping loud vol on whoa crushing passed bull

  Buy

• OptionRogue

  Jun 2, 2024

  $OVID keeping heater clean vibes now dripping level-to-level vibes range uptrend uptrend

  Buy

• CapitalCarnage

  May 13, 2024

  $OVID theta cliff doom keeping here on noise no trend noise broken nimble rip heavy

  Sell

• OptionSpectre

  Feb 5, 2024

  $OVID out hard spike feels queued levels vol steady humming lower vibes clear

  Sell